2022年10月1日 · Since the newer XPO1 inhibitor eltanexor (elta) is given 5 days/week in early-phase clinical studies, we compared the antileukemic effects of intermittent (2d/w) and …

2022年11月15日 · To extend this concept to include a broader range of targeted drug combinations directed against MRD relapse, we developed the Australasian Leukaemia and …

In this study, we evaluated whether inhibition of SIK3 with the tool compound YKL-05-099 can suppress MEF2C function and attenuate disease progression in animal models of AML. …

aml的诊断标准参照who 2016造血和淋巴组织肿瘤分类标准，外周血或骨髓原始细胞≥20%是诊断aml的必要条件。 但当患者被证实有克隆性重现性细胞遗传学异常t（8;21）（q22；q22） …

XPO1 inhibition by selinexor (seli) leads to NPM1c nuclear relocalization, loss of HOX expression, and terminal differentiation. However, 2 days/week seli did not result in evident benefit for …

2022年10月1日 · Poster: AML-099 Prolonged XPO1 Inhibition Is Essential for Optimal Anti-Leukemic Activity in NPM1-Mutated AML October 2022 Clinical Lymphoma, Myeloma and …

Context: RARA-positive AML is a novel, genomically defi ned subset with an actionable target for treatment with tamibarotene, an oral and selective RAR agonist (McKeown 2017). In a …

AML-099 Prolonged XPO1 Inhibition Is Essential for Optimal Anti-Leukemic Activity in NPM1-Mutated AML

2020年1月2日 · In this study, we evaluated whether inhibition of SIK3 with the tool compound YKL-05-099 can suppress MEF2C function and attenuate disease progression in animal …

2022年10月1日 · XPO1 inhibition by selinexor (seli) leads to NPM1c nuclear relocalization, loss of HOX expression, and terminal differentiation. However, 2 days/week seli did not result in …